Sponsored by:

Duke MMIL designs novel SPECT/CT system for 3D breast imaging

Jul 17, 2007
2007 07 17 15 08 50 706
2007 07 17 15 08 50 706
Image courtesy of Duke University Medical Center Multi-Modality Imaging Lab.

close

Latest in Molecular Imaging
Ame 2018 12 11 00 02 7009 Atom Nuclear Lab 400
SNMMI updates radioisotope production status in U.S.
October 10, 2025
Expand your field of view with new Biograph Trinion.X PET/CT
Sponsored
Expand your field of view with new Biograph Trinion.X PET/CT
October 6, 2025
Semaglutide Injection Pen
GLP-1 drugs may confound PET/CT imaging findings
October 7, 2025
Prostate Imaging
PSMA PET-guided radiotherapy shows promise
October 3, 2025
Related Stories
2007 07 17 14 38 39 706
Molecular Imaging
Duke MMIL designs novel SPECT/CT system for 3D breast imaging
2007 07 17 14 32 28 706
Molecular Imaging
Duke MMIL designs novel SPECT/CT system for 3D breast imaging
2007 06 25 10 54 15 706
Molecular Imaging
Studies link Alzheimer's to beta-amyloid and potential for new ligand
Expand your field of view with new Biograph Trinion.X PET/CT
Sponsor Content
Expand your field of view with new Biograph Trinion.X PET/CT
More in Molecular Imaging
SNMMI updates radioisotope production status in U.S.
By AuntMinnie.com staff writers
Projects noted in an October 10 update include IAEA's disused radium transfer program and others.
October 10, 2025
Ame 2018 12 11 00 02 7009 Atom Nuclear Lab 400
PSMA-PET/CT may replace NaF-PET/CT in advanced prostate cancer
By Will Morton
Replacing F-18 sodium fluoride (NaF) PET/CT with F-18 PSMA PET/CT can improve treatment for men with newly diagnosed prostate cancer.
October 10, 2025
2025 10 09 Jnumed Psma Pet Vs Na F Pet Thumbnail
GLP-1 drugs may confound PET/CT imaging findings
By AuntMinnie.com staff writers
The drugs are now widely prescribed for people with type 2 diabetes -- with a 700% use increase in the U.S. between 2019 and 2023.
October 7, 2025
Semaglutide Injection Pen
PSMA PET-guided radiotherapy shows promise
By Will Morton
A trial demonstrated that radiotherapy informed by PSMA-PET led to improved outcomes in prostate cancer patients.
October 3, 2025
Prostate Imaging
PET reveals mechanism underlying brain fog in long COVID
By Will Morton
Brain regions where C-11 K-2 radiotracer was increased were negatively correlated with long-COVID patients’ performance on cognitive tests.
October 2, 2025
2025 10 02 Long Covid Apar Thumbnail
SpectronRx’s Ac-225 boosted for use in Canada
By AuntMinnie.com staff writers
Ac-225 is a highly sought-after alpha-emitting isotope that shows promise for targeted cancer therapy.
October 1, 2025
Isotopes1
NAPT survey results show promise for proton therapy adoption
By Amerigo Allegretto
Proton therapy continues to experience increased clinical use, but barriers to care continue to limit its potential.
September 29, 2025
Survey Form 400
CPDC launches Cadena Research for radiopharmaceutical development
By AuntMinnie.com staff writers
The CPDC has launched Cadena Research, a new preclinical CRO offering support for early-stage radiopharmaceuticals.
September 29, 2025
Radiotherapy2 400
Case report: Pluvicto as a first-line treatment in late-stage prostate cancer
Since 1996, the patient continually declined androgen deprivation therapy, chemotherapy, and local therapy to the prostate gland.
September 26, 2025
Burden of PSMA-expressing prostate cancer before and after treatment with two cycles of Lu-177 PSMA-617. (A and B) Reduction in overall disease burden is evident after treatment. Avidity of patient’s primary prostate tumor and his osseous metastasis shown before (C) and after (D) treatment.
Lantheus and GEHC to launch PET agent for prostate imaging in Japan
By AuntMinnie.com staff writers
GEHC will draw on its manufacturing network and R&D expertise following its acquisition in March 2025 of Nihon Medi-Physics.
September 24, 2025
Prostate Imaging
NorthStar partners with Univ. of Wisconsin on radiopharma research
By AuntMinnie.com staff writers
The multiyear project furthers the goal of turning southern Wisconsin into a nuclear medicine hub.
September 23, 2025
Ame 2018 12 11 00 02 7009 Atom Nuclear Lab 400
Adding MBI to DBT finds more breast cancers
By Amerigo Allegretto
Adding molecular breast imaging (MBI) to DBT screening leads to more invasive cancers detected in women with dense breasts.
September 23, 2025
Images in a 62-year-old woman who presented for screening. (A) Image from DBT screening (the synthesized 2D mediolateral oblique view of the left breast is shown) at year on was interpreted as negative and showing heterogeneously dense breast. (B) Image from molecular breast imaging screening (mediolateral oblique view) at year one reveals a 0.9-cm non-mass focal area of uptake in the left breast (arrow). (C) Targeted ultrasound scan (transverse image) shows a suspicious mass in the 3-o’clock position of the left breast, 4 cm from the nipple. Ultrasound-guided core biopsy and lumpectomy revealed a 0.9-cm grade 2 invasive ductal carcinoma, an estrogen receptor–negative, progesterone receptor–negative, human epidermal growth factor receptor 2–negative lesion, with two sentinel nodes negative (N0).
Page 1 of 615
Next Page